10 20 30 40 50 60 70 80 2HIE - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER CYTOKINE 07-JUN-94 2HIE
TITLE A HOMOLOGY MODEL OF HUMAN INTERFERON ALPHA-2
COMPND MOL_ID: 1; COMPND 2 MOLECULE: INTERFERON ALPHA-2B; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES
SOURCE MOL_ID: 1
KEYWDS CYTOKINE
EXPDTA THEORETICAL MODEL
AUTHOR N.J.MURGOLO,W.T.WINDSOR,A.HRUZA,S.EALICK,P.REICHERT, AUTHOR 2 P.P.TROTTA
REVDAT 1 31-AUG-94 2HIE 0
JRNL AUTH N.J.MURGOLO,W.T.WINDSOR,A.HRUZA,P.REICHERT, JRNL AUTH 2 A.TSARBOPOULOS,S.BALDWIN,E.HUANG,B.PRAMANIK, JRNL AUTH 3 S.EALICK,P.P.TROTTA JRNL TITL A HOMOLOGY MODEL OF HUMAN INTERFERON ALPHA-2. JRNL REF PROTEINS V. 17 62 1993 JRNL REFN ASTM PSFGEY US ISSN 0887-3585
REMARK 1
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : NULL REMARK 3 AUTHORS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4 REMARK 4 2HIE COMPLIES WITH FORMAT V. 2.3, 09-JULY-1998
REMARK 5 REMARK 5 THIS MODEL IS BASED UPON THE MURINE BETA INTERFERON X-RAY REMARK 5 STRUCTURE FOUND IN PDB ENTRY 1IFA.
REMARK 6 REMARK 6 PUTATIVE HUMAN INTERFERON ALPHA-2B ACTIVE SITE ACT CONSISTS REMARK 6 OF RESIDUES 24 - 52, 69 - 79, 134 - 140.
REMARK 7 REMARK 7 THE SEQUENCE HAS BEEN REPORTED IN PATENT NUMBER REMARK 7 EP0032134-A/15, AUTHOR C.WEISSMANN, GRANTED TO BIOGEN REMARK 7 ON JULY 15, 1981. A COMPLETE COPY OF THE SEQUENCE IS REMARK 7 DEPOSITED IN THE ATLAS VERSION 4, PIR VERSION 40, ENTRY REMARK 7 PATCHX:A12093 AND A PARTIAL GENOMIC SEQUENCE IN GENBANK REMARK 7 VERSION 38, ENTRY GB_PR:S64991.
REMARK 220 REMARK 220 EXPERIMENTAL DETAILS REMARK 220 EXPERIMENT TYPE : THEORETICAL MODELLING REMARK 220 REMARK 220 REMARK: NULL
REMARK 225 REMARK 225 THEORETICAL MODEL REMARK 225 THE COORDINATES IN THIS ENTRY REPRESENT A MODEL STRUCTURE. REMARK 225 PROTEIN DATA BANK CONVENTIONS REQUIRE THAT CRYST1 AND REMARK 225 SCALE RECORDS BE INCLUDED, BUT THE VALUES ON THESE REMARK 225 RECORDS ARE MEANINGLESS.
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE A 27 156.77 122.42 REMARK 500 GLN A 40 160.30 72.82 REMARK 500 ASP A 71 -74.93 64.64 REMARK 500 SER A 73 -92.41 149.68 REMARK 500 VAL A 99 -57.04 58.56 REMARK 500 VAL A 103 -95.62 37.73 REMARK 500 THR A 106 -56.58 74.83 REMARK 500 THR A 108 129.22 97.34 REMARK 500 TYR A 135 163.05 64.59 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 CYS A 1 ASP A 2 -149.56 REMARK 500 ASP A 32 ARG A 33 -147.09
DBREF 2HIE A 1 165 PIR I78570 I78570 1 165
SEQRES 1 A 165 CYS ASP LEU PRO GLN THR HIS SER LEU GLY SER ARG ARG SEQRES 2 A 165 THR LEU MET LEU LEU ALA GLN MET ARG ARG ILE SER LEU SEQRES 3 A 165 PHE SER CYS LEU LYS ASP ARG HIS ASP PHE GLY PHE PRO SEQRES 4 A 165 GLN GLU GLU PHE GLY ASN GLN PHE GLN LYS ALA GLU THR SEQRES 5 A 165 ILE PRO VAL LEU HIS GLU MET ILE GLN GLN ILE PHE ASN SEQRES 6 A 165 LEU PHE SER THR LYS ASP SER SER ALA ALA TRP ASP GLU SEQRES 7 A 165 THR LEU LEU ASP LYS PHE TYR THR GLU LEU TYR GLN GLN SEQRES 8 A 165 LEU ASN ASP LEU GLU ALA CYS VAL ILE GLN GLY VAL GLY SEQRES 9 A 165 VAL THR GLU THR PRO LEU MET LYS GLU ASP SER ILE LEU SEQRES 10 A 165 ALA VAL ARG LYS TYR PHE GLN ARG ILE THR LEU TYR LEU SEQRES 11 A 165 LYS GLU LYS LYS TYR SER PRO CYS ALA TRP GLU VAL VAL SEQRES 12 A 165 ARG ALA GLU ILE MET ARG SER PHE SER LEU SER THR ASN SEQRES 13 A 165 LEU GLN GLU SER LEU ARG SER LYS GLU
FTNOTE 1 CYS 1 - ASP 2 OMEGA = 210.44 PEPTIDE BOND DEVIATES FTNOTE 1 SIGNIFICANTLY FROM TRANS CONFORMATION FTNOTE 2 ASP 32 - ARG 33 OMEGA = 212.91 PEPTIDE BOND DEVIATES FTNOTE 2 SIGNIFICANTLY FROM TRANS CONFORMATION
HELIX 1 A THR A 6 ARG A 23 1 18 HELIX 2 B ILE A 53 SER A 68 1 16 HELIX 3 C LEU A 80 GLN A 91 1 12 HELIX 4 D ILE A 116 LYS A 133 1 18 HELIX 5 E GLU A 141 ASN A 156 1 16
SSBOND 1 CYS A 1 CYS A 98 SSBOND 2 CYS A 29 CYS A 138
SITE 1 ACT 47 ILE A 24 SER A 25 LEU A 26 PHE A 27 SITE 2 ACT 47 SER A 28 CYS A 29 LEU A 30 LYS A 31 SITE 3 ACT 47 ASP A 32 ARG A 33 HIS A 34 ASP A 35 SITE 4 ACT 47 PHE A 36 GLY A 37 PHE A 38 PRO A 39 SITE 5 ACT 47 GLN A 40 GLU A 41 GLU A 42 PHE A 43 SITE 6 ACT 47 GLY A 44 ASN A 45 GLN A 46 PHE A 47 SITE 7 ACT 47 GLN A 48 LYS A 49 ALA A 50 GLU A 51 SITE 8 ACT 47 THR A 52 THR A 69 LYS A 70 ASP A 71 SITE 9 ACT 47 SER A 72 SER A 73 ALA A 74 ALA A 75 SITE 10 ACT 47 TRP A 76 ASP A 77 GLU A 78 THR A 79 SITE 11 ACT 47 LYS A 134 TYR A 135 SER A 136 PRO A 137 SITE 12 ACT 47 CYS A 138 ALA A 139 TRP A 140
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000